18-Month Study on Vogelxo Testosterone Gel’s Impact on Vision and Eye Health in Males

Introduction

Testosterone replacement therapy (TRT) has become increasingly prevalent among American males seeking to address symptoms associated with low testosterone levels. Vogelxo, a popular testosterone gel, is one such treatment option. While the benefits of TRT are well-documented, its potential effects on vision and eye health have not been extensively explored. This article presents the findings of an 18-month ophthalmological study examining the impact of Vogelxo testosterone gel on the vision and eye health of American males.

Study Design and Methodology

The study involved 200 American males aged 40-65 years with confirmed low testosterone levels who were prescribed Vogelxo testosterone gel. Participants underwent comprehensive ophthalmological examinations at baseline, 6 months, 12 months, and 18 months. Examinations included visual acuity testing, intraocular pressure measurement, slit-lamp biomicroscopy, and fundus photography. Participants also completed questionnaires regarding any changes in their vision or ocular symptoms.

Results: Visual Acuity and Refractive Changes

Over the 18-month study period, no significant changes in visual acuity were observed among the participants using Vogelxo testosterone gel. The mean logMAR visual acuity remained stable at 0.02 ± 0.05 at baseline and 0.03 ± 0.06 at 18 months. However, a small subset of participants (n=12, 6%) reported subjective improvements in their near vision, which may be attributed to the potential neuroprotective effects of testosterone on the visual system.

Regarding refractive changes, the study found a slight increase in the prevalence of myopia among participants. At baseline, 22% of participants were myopic, which increased to 26% by the end of the study. While this change was not statistically significant, it warrants further investigation to determine if testosterone therapy may influence ocular growth or corneal curvature.

Results: Intraocular Pressure and Glaucoma Risk

The study monitored intraocular pressure (IOP) as a potential risk factor for glaucoma. The mean IOP remained within the normal range throughout the study, with values of 15.2 ± 2.1 mmHg at baseline and 15.4 ± 2.3 mmHg at 18 months. No participants developed glaucoma during the study period. However, two participants (1%) with pre-existing ocular hypertension required adjustments to their glaucoma medications, suggesting that testosterone therapy may influence IOP in susceptible individuals.

Results: Anterior Segment and Dry Eye Symptoms

Slit-lamp biomicroscopy revealed no significant changes in the anterior segment of the eye among participants using Vogelxo testosterone gel. However, a notable increase in self-reported dry eye symptoms was observed, with 18% of participants reporting dry eye at baseline compared to 28% at 18 months. This finding aligns with previous research suggesting that testosterone may influence tear film stability and meibomian gland function.

Results: Posterior Segment and Retinal Health

Fundus photography and ophthalmoscopy demonstrated no significant changes in the posterior segment of the eye among study participants. No cases of retinal pathology, such as diabetic retinopathy or age-related macular degeneration, were attributed to the use of Vogelxo testosterone gel. However, one participant (0.5%) developed a choroidal nevus during the study, which was deemed unrelated to the testosterone therapy.

Discussion and Clinical Implications

The findings of this 18-month ophthalmological study suggest that Vogelxo testosterone gel has a generally favorable safety profile regarding vision and eye health in American males. No significant adverse effects on visual acuity, intraocular pressure, or retinal health were observed. However, the study highlights the need for further research into the potential association between testosterone therapy and myopia, as well as the increased prevalence of dry eye symptoms among users.

Clinicians prescribing Vogelxo testosterone gel should be aware of these findings and counsel patients accordingly. Regular ophthalmological examinations are recommended for patients undergoing long-term testosterone therapy, particularly those with pre-existing ocular conditions or risk factors for glaucoma and dry eye disease.

Conclusion

This longitudinal study provides valuable insights into the impact of Vogelxo testosterone gel on vision and eye health in American males. While the overall safety profile appears favorable, the potential for increased dry eye symptoms and a slight increase in myopia prevalence warrants further investigation. As testosterone replacement therapy continues to gain popularity, ongoing research and monitoring of its ocular effects are essential to ensure the long-term health and well-being of American males undergoing this treatment.

Contact Us For HGH And Sermorelin Injection Treatment

Name (*)
Email (*)
Phone (*)
Select A Program (*)	HGH TherapyHGH InjectionsTestosterone InjectionsCo-Created ProgramTestosterone TherapyAt Home HRT ProgramSermorelin InjectionsIpamorelinPeptidesWeight ManagementHuman Growth HormoneShort Height TherapyGender DysmorphiaHormone TreatmentBlood PanelTesamorelinOther
Select US State (*)	U.S.A.AlabamaAlaskaArizonaArkansasCaliforniaCanadaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaPuerto RicoRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahU.S. Virgin IslandsVermontVirginiaWashingtonWashington,DCWest VirginiaWisconsinWyomingCanada
Select Age (30+ only)	Over 2930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475+

List of USA state clinics - click a flag below for blood testing clinics.

Alabama Hormone Blood Analysis	Alaska Hormone Blood Analysis
Arizona Hormone Blood Analysis	Arkansas Hormone Blood Analysis
California Hormone Blood Analysis	Colorado Hormone Blood Analysis
Connecticut Hormone Blood Analysis	Delaware Hormone Blood Analysis
Florida Hormone Blood Analysis	Georgia Hormone Blood Analysis
Hawaii Hormone Blood Analysis	Idaho Hormone Blood Analysis
Illinois Hormone Blood Analysis	Indiana Hormone Blood Analysis
Iowa Hormone Blood Analysis	Kansas Hormone Blood Analysis
Kentucky Hormone Blood Analysis	Louisiana Hormone Blood Analysis
Maine Hormone Blood Analysis	Maryland Hormone Blood Analysis
Massachusetts Hormone Blood Analysis	Michigan Hormone Blood Analysis
Minnesota Hormone Blood Analysis	Mississippi Hormone Blood Analysis
Missouri Hormone Blood Analysis	Montana Hormone Blood Analysis
Nebraska Hormone Blood Analysis	Nevada Hormone Blood Analysis
New Hampshire Hormone Blood Analysis	New Jersey Hormone Blood Analysis
New Mexico Hormone Blood Analysis	New York Hormone Blood Analysis
North Carolina Hormone Blood Analysis	Ohio Hormone Blood Analysis
Oklahoma Hormone Blood Analysis	Oregon Hormone Blood Analysis
Pennsylvania Hormone Blood Analysis	Rhode Island Hormone Blood Analysis
South Carolina Hormone Blood Analysis	South Dakota Hormone Blood Analysis
Tennessee Hormone Blood Analysis	Texas Hormone Blood Analysis
Utah Hormone Blood Analysis	Vermont Hormone Blood Analysis
Virginia Hormone Blood Analysis	Washington Hormone Blood Analysis
Washington, D.C. Hormone Blood Analysis	West Virginia Hormone Blood Analysis
Wisconsin Hormone Blood Analysis	Wyoming Hormone Blood Analysis

Word Count: 653